Live Webcast at 12 noon EDT on Tuesday, July 25
ALAMEDA, Calif.--(BUSINESS WIRE)--Jul. 18, 2017--
BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company
developing and commercializing products addressing degenerative
diseases, announced today that it will host a Key Opinion Leader event
on the topic of dry age-related macular degeneration (AMD) in New York
City on Tuesday, July 25. The meeting will feature a presentation by key
opinion leader David S. Boyer, MD, Retina-Vitreous Associates, who will
discuss the clinical perspective and cell therapy treatment options for
patients with dry age-related macular degeneration.
Dr. Boyer is a world-renowned clinician, surgeon and educator. He
completed his medical degree at the Chicago Medical School. In 1976, he
finished his residency at the U.S.C. County Medical Center. A yearlong
retinal surgery fellowship at the Wills Eye Hospital, located in
Philadelphia, completed his training. He is currently a leading
investigator for various national clinical trials on retinal diseases
and serves as an advisor for multiple research, educational and
BioTime's management team will also provide an overview of the Company’s
ongoing clinical development work with OpRegen®, being
studied for patients with dry AMD, including recently presented new
clinical trial data from this year's Annual Meeting of the Association
for Research in Vision and Ophthalmology (ARVO). OpRegen is now in a
Phase I/IIa dose finding study to evaluate its safety and efficacy in
patients who have an advanced stage of the disease, and has received
fast track designation by the FDA.
The lunch event is intended for institutional investors, sell-side
analysts, investment bankers, and business development professionals
only. Please RSVP in advance to Mac@LifeSciAdvisors.com
if you plan to attend in person, as space is limited.
A live webcast of the event, with slides, will be available at http://lifesci.rampard.com/20170725/reg.jsp
and within the Investors section of the Company’s website at www.biotimeinc.com.
BioTime, Inc. is a clinical-stage biotechnology company focused on
developing and commercializing novel therapies developed from what the
company believes to be the world’s premier collection of pluripotent
cell assets. The foundation of BioTime’s core therapeutic technology
platform is pluripotent cells that are capable of becoming any of the
cell types in the human body. Pluripotent cells have potential
application in many areas of medicine with large unmet patient needs,
including various age-related degenerative diseases and degenerative
conditions for which there presently are no cures. Unlike
pharmaceuticals that require a molecular target, therapeutic strategies
based on the use of pluripotent cells are generally aimed at
regenerating or replacing affected cells and tissues, and therefore may
have broader applicability than pharmaceutical products. BioTime also
has significant equity holdings in two publicly traded companies,
Asterias Biotherapeutics, Inc. and OncoCyte Corporation, which BioTime
founded and which, until recently, were majority-owned consolidated
subsidiaries of BioTime.
BioTime common stock is traded on the NYSE MKT and TASE under the symbol
BTX. For more information, please visit www.biotimeinc.com
or connect with the company on Twitter, LinkedIn, Facebook, YouTube, and
View source version on businesswire.com: http://www.businesswire.com/news/home/20170718005492/en/
Source: BioTime, Inc.
EVC Group, Inc.
Contact for BioTime:
JQA Partners, Inc.